Sterling Biotech Limited reported unaudited standalone earnings results for the fourth quarter and full year ended December 31, 2015. For the quarter, the company reported net sales/income from operations was INR 863.094 million against INR 1,216.282 million for the same period in the last year. Loss from operations before other income and finance costs was INR 644.759 million against INR 723.487 million a year ago. Loss from ordinary activities after finance costs before tax was INR 1,536.759 million against INR 1,599.470 million for the same period in the last year. Net loss for the period was INR 1,038.159 million or INR 2.40 per diluted share after extraordinary items against INR 1,080.570 million or INR 2.94 per diluted share after extraordinary items for the same period in the last year.

For the full year, the company reported net sales/income from operations was INR 4,108.694 million against INR 6,669.507 million for the same period in the last year. Loss from operations before other income and finance costs was INR 2,259.645 million against INR 1,616.548 million a year ago. Loss from ordinary activities after finance costs before tax was INR 5,578.482 million against INR 6,311.605 million for the same period in the last year. Net loss for the period was INR 3,768.482 million or INR 8.70 per diluted share after extraordinary items against INR 4,263.805 million or INR 10.57 per diluted share after extraordinary items for the same period in the last year.